Prescriptions of obesity management drugs (OMDs) have increased, and these increasing trends are associated with onli ...

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...

A recent study published in JAMA Psychiatry has uncovered promising evidence suggesting that glucagon-like peptide-1 (GLP-1) receptor agonists, particularly semaglutide and liraglutide, may be ...

Ozempic can cause bone density loss and I didn't think that would happen to me because I was only on it for a year. But I ...

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers.

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...